<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:126750137;
mso-list-template-ids:776531278;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1843617345;
mso-list-template-ids:1470398658;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://donaghue.org/wp-content/uploads/Another-Look-2020-grant-announcement.pdf__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBToykYgA$" target="_blank">Donaghue Foundation: Research to Improve Health of Older Adults in Long-Term Care Facilities</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Donaghue Foundation welcomes applications to its Another Look 2020 grant program. The program supports health-related research projects with the potential to improve the quality of care and life for
adults age 65 or older who are long-term residents living in nursing homes, assisted living facilities, and other congregate care facilities. The foundation welcomes all topics related to improving quality in long-term care facilities but is particularly interested
in supporting the following topics: increasing the availability and use of palliative, end of life, and hospice care; assessing the impact of innovations in staffing roles and expertise on resident quality of life; assessing the role of family members and
informal caregivers on resident quality of life; understanding and reducing the impact of ageism on resident health and well-being; reducing isolation and loneliness and their negative impact on resident health and well-being; addressing racial, ethnic, gender
or income disparities in care quality or health outcomes; and enhancing understanding of the specialized care needs of resident populations with developmental disabilities or with serious mental illness. In 2020, the foundation will invest a total of approximately
$750,000 in the program and expects to make four or five awards. Projects may be up to two years in length.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due March 25, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: March 12.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.fahsbeckfund.org/grant_programs.html__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBewbdGpk$" target="_blank">Fahs-Beck Fund for Research and Experimentation: Faculty/Post-Doctoral Grant Program (Fahs-Beck Fellows)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Grants of up to $20,000 are available to help support the research of faculty members or post-doctoral researchers affiliated with non-profit human service organizations in the United States and Canada.
Areas of interest to the Fund are: <b>studies to develop, refine, evaluate, or disseminate innovative interventions designed to prevent or ameliorate major social, psychological, behavioral or public health problems affecting children, adults, couples, families,
or communities, or studies that have the potential for adding significantly to knowledge about such problems</b>. The research for which funding is requested must focus on the United States or Canada or on a comparison between the United States or Canada and
one or more other countries.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 1, 2020 and November 1, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for April 1, 2020 deadline: March 19.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.alzdiscovery.org/research-and-grants/funding-opportunities/harrington__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBkQfScFE$" target="_blank">ADDF-Harrington Scholar Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and committed project
support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. Average award: Up to $600,000 over 2 years with dedicated support from a team of industry
veterans with capabilities that include medicinal chemistry, pharmacology and toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due April 20, 2020. Application due July 31, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for April 20, 2020 letter of intent deadline: April 7.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.sfari.org/grant/2020-sfari-collaboration-on-sex-differences-in-autism-request-for-applications?tab=faq__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBKJrDQRg$" target="_blank">Simons Foundation Autism Research Initiative (SFARI): Collaboration
on Sex Differences in Autism</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">SFARI Collaborations are a new funding mechanism that will provide substantive and stable funding support to multidisciplinary teams of investigators tackling critical issues in the autism research field.
Collaborations will be led by a director who oversees interdisciplinary, synergistic research efforts across multiple laboratories. Investigative groups within a Collaboration will focus on the same conceptually unified topic but will incorporate different
scientific disciplines, multiple levels of analysis, and will include a robust data-sharing infrastructure. SFARI Collaborations have a maximum budget of up to $8,000,000, including 20 percent indirect costs, over an initial period of four years, with a possible
three-year extension.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due April 21, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: April 8.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-011.html__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBKrlUye8$" target="_blank">Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung,
and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single-site, biphasic, late-stage implementation and translation (T4) research trials to identify and test pragmatic
and sustainable implementation strategies that will increase the use of evidence-based practices (EBP), i.e., evidence-based guidelines or other well-accepted evidence-based interventions, for preventing and/or managing heart, lung, and blood diseases and/or
sleep (HLBS) disorders. Applicants will be expected to address a planning phase (R61) of up to one year, and an implementation research phase (R33) of up to four years for the clinical trial. During the planning phase awardees will be expected to: finalize
selection of the EBP; recruit participating organization(s); prepare the implementation protocol; develop milestones and a project timeline; and develop plans for data collection and management, and participant recruitment and retention. Robust plans for the
implementation research clinical trial and the supporting implementation strategy dissemination package are required for the R33 phase of the application. Upon administrative review by the NHLBI, only meritorious R61 projects that meet the predetermined scientific
milestones will be selected to transition to the R33 phase. Investigators with expertise in T4 clinical trials and hybrid studies for heart, lung, blood, or sleep conditions are expected to be part of the research team. In addition, applications proposing
collaborative investigative teams combining expertise in qualitative methods, administration of T4 implementation clinical trials as appropriate at various levels (e.g., individual, clinical practice, facility, etc.), quality improvement, health economics,
implementation of skills development programs, and robust experience in the adaptation and implementation of other established EBP will be encouraged. Personnel involved in the proposed strategy, e.g., nurse practitioners, patient, family members, respiratory
therapists, pharmacists, hospital intensivists, etc., should be meaningfully engaged in the conceptualization and the planned execution of the proposed project. Applications proposing to establish a new EBP are not within the scope of this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 1, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: April 20.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-079.html__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBZVAYnTg$" target="_blank">Surgical Disparities Research (R01 – Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority
and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional
and systems level.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 5, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: April 22.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-054.html__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBntapNrs$" target="_blank">Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact
of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 11, 2020 and May 11, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for May 11, 2020 deadline: April 28.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-007.html__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBJJvRd1w$" target="_blank">Leadership Award for Alzheimer’s Disease and Related Dementias Research (R35 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Applicants will be supported to develop and implement innovative multidisciplinary research and mentoring programs through an interchange of ideas that enable individuals and their institutions to strengthen
existing programs and the development of new research programs that are specific to the goals/milestones of the NIH Alzheimer's Disease and Alzheimer's Disease Related Dementias Summits.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 19, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: May 27.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-090.html__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBHK3WBqY$" target="_blank">NIAMS Clinical Trial Planning Grant (R34) – Clinical Trial Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to enable the necessary planning,
design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant or documentation that planning has been addressed is required prior to submission
of an application through a NIAMS U01 clinical trial implementation application that will support the actual implementation and conduct of the study. The planning should facilitate the launching of a trial that is hypothesis-driven, milestone-defined, and
has the potential for high impact within the research mission of the NIAMS.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 1, 2020; November 2, 2020; March 1, 2021; July 1, 2021; November 1, 2021; March 1, 2022; July 1, 2022; and November 1, 2022.
<span style="color:red">ed-RA deadline to receive draft documents for July 1, 2020 deadline: June 18.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5686&WT.mc_id=USNSF_39&WT.mc_ev=click__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmB4hmIAwM$" target="_blank">NSF: Perception, Action & Cognition</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The PAC program funds theoretically motivated research on a wide-range of topic areas related to typical human behavior with particular focus on perceptual, motor, and cognitive processes and their interactions.
Central research topics for consideration by the program include (but are not limited to) vision, audition, haptics, attention, memory, written and spoken language, spatial cognition, motor control, categorization, reasoning, and concept formation. Of particular
interest are emerging areas, such as the interaction of sleep or emotion with cognitive or perceptual processes, epigenetics of cognition, computational models of cognition, and cross-modal and multimodal processing. The program welcomes a wide range of perspectives,
such as individual differences, symbolic and neural-inspired computation, ecological approaches, genetics and epigenetics, nonlinear dynamics and complex systems, and a variety of methodologies spanning the range of experimentation and modeling. The PAC program
is open to co-review of proposals submitted to other programs both within the Social, Behavioral, and Economic Sciences Directorate and across other directorates.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Note: Proposals may be returned without review if the major focus is 1) the organization of neural activity or brain networks; 2) understanding clinical populations; or 3) non-human animals without a clear
and direct impact on our understanding of human perception, action, or cognition. Investigators are encouraged to send the program director a one-page summary of the proposed research before submitting a proposal, in order to determine its appropriateness
for the PAC program.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due August 3, 2020. <span style="color:red">
Med-RA deadline to receive draft documents: July 21.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504696&WT.mc_id=USNSF_39&WT.mc_ev=click__;!!PhOWcWs!hEIGnl31jNOWsTQc1K-b0ammchnhJ4aHCqt4qrKiFdS7_9lhxMAg-2SlBlm06_rAWTYelA5FqPmBEzg2FZw$" target="_blank">NSF: Science of Organizations</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Organizations -- private and public, established and entrepreneurial, designed and emergent, formal and informal, profit and nonprofit -- are critical to the well-being of nations and their citizens. They
are of crucial importance for producing goods and services, creating value, providing jobs, and achieving social goals. The Science of Organizations (SoO) program funds basic research that yields a scientific evidence base for improving the design and emergence,
development and deployment, and management and ultimate effectiveness of organizations of all kinds.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">SoO funds research that advances our fundamental understanding of how organizations develop, form and operate. Successful SoO research proposals use scientific methods to develop and refine theories, to
empirically test theories and frameworks, and to develop new measures and methods. Funded research is aimed at yielding generalizable insights that are of value to the business practitioner, policy-maker and research communities.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">SoO welcomes any and all rigorous, scientific approaches that illuminate aspects of organizations as systems of coordination, management and governance.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">In considering whether a particular project might be a candidate for consideration by SoO, please note:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Intellectual perspectives may involve (but are not limited to) organizational theory, behavior, sociology or economics, business policy and strategy, communication sciences,
entrepreneurship, human resource management, information sciences<i>,</i> managerial and organizational cognition, operations management, public administration, social or industrial psychology, and technology and innovation management.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Phenomena studied may include (but are not limited to) structures, routines, effectiveness, competitiveness, innovation, dynamics, change and evolution.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Levels of analysis may include (but are not limited to) organizational, cross-organizational collaborations or relationships, and institutional and can address individuals,
groups or teams.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Research methods may be qualitative and quantitative and may include (but are not limited to) archival analyses, surveys, simulation studies, experiments, comparative case
studies, and network analyses.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">Projects that aim to implement and subsequently evaluate particular organizational training, effectiveness or change programs, rather than to advance fundamental, generalizable knowledge, are not appropriate
for SoO.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due September 3, 2020.
<span style="color:red">Med-RA deadline to receive draft documents: August 24.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-family:Palatino;color:red">.</span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
</div>
</body>
</html>